Skip to contentN
Nika Pharmaceuticals, Inc
N
NIKANika Pharmaceuticals, Inc Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$37.07K-$37.07KderivedN/M vs Q4 2024 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$37,073N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR
Operating Cash Flowderived-$38,858N/M ended Dec 31, 2025 · filed Mar 25, 2026 · 84 d after period end